Did insulin prices go up recently?

Editorial team Published on

No, insulin prices have actually decreased recently due to legislative caps and voluntary price cuts by major manufacturers.

Recent Price Trends

  • Average Cost Drops: The average price per insulin unit dropped significantly, reaching historic lows in recent years.
  • Manufacturer Cuts: Major insulin makers like Novo Nordisk, Eli Lilly, and Sanofi reduced list prices or instituted strict monthly out-of-pocket caps.
  • Capped Expenses: Under the Inflation Reduction Act, Medicare recipient costs are capped at $35 per month for covered insulin, and many commercial plans or manufacturer savings programs offer similar $35 caps.

You can check current brand pricing details or look for discounts using resources like GoodRx.

Is insulin going to be cheaper in 2026?

Yes, insulin is becoming cheaper in 2026 due to expanded federal caps, new nonprofit manufacturing options, and lower list prices from major drug companies.

Key Affordability Changes in 2026

  • Medicare Caps and Reductions: The $35 monthly out-of-pocket cap for Medicare beneficiaries remains fully in place with no deductible required. Additionally, Medicare Part D out-of-pocket drug spending is capped at $2,100 total for the year, helping patients with complex diabetes needs.
  • New Low-Cost Options: Nonprofit manufacturer Civica Rx launched an affordable generic long-acting insulin (insulin glargine-yfgn) priced at a wholesale cost of $45 for five pens and a maximum retail price of $55 per box.
  • Manufacturer Programs and Biosimilars: Major insulin makers (Eli Lilly, Novo Nordisk, and Sanofi) have active voluntary programs capping out-of-pocket costs at $35 per month for many consumers, alongside low-cost generic biosimilars available at various retail pharmacies.
  • State-Level Laws: States like California implemented new rules capping co-pays at $35 per month for state-regulated private health plans and restricting deductibles on insulin.

Why did the price of insulin go up so much?

The price of insulin increased dramatically in the United States due to a concentrated market, a flawed rebate system involving industry middlemen, and a lack of direct price regulation.

Key Drivers of High Insulin Prices

  • Market Monopoly (The "Big Three"): The U.S. insulin market is controlled by three major pharmaceutical manufacturers—Eli Lilly, Sanofi, and Novo Nordisk. With virtually no broad competition, these companies have historically raised list prices in lockstep.
  • The Rebate and Middleman System: Pharmacy benefit managers (PBMs) negotiate drug coverage on behalf of insurers and employers. PBMs favor drugs that offer high rebates, which incentivizes manufacturers to continually raise list prices to secure preferred placement on insurance formularies.
  • Patent Manipulation ("Evergreening"): Manufacturers continuously make minor, incremental changes to newer insulin formulations and delivery devices (like pens) while patenting these updates. This blocks generic or biosimilar competitors from entering the market affordably.
  • High-Deductible Health Plans: Rising list prices heavily impact uninsured patients or those with high-deductible health plans, forcing them to pay the inflated sticker price out-of-pocket before insurance kicks in.

Is insulin still $35 for Medicare patients?

Yes, insulin is still capped at no more than $35 per month for a one-month supply of each covered insulin product for Medicare patients.

Key Details on the $35 Insulin Cap

  • Medicare Part D: Covers retail injectable and inhaled insulin, capping costs at $35 per month per product with no deductible.
  • Medicare Part B: Covers insulin used through a traditional traditional durable medical equipment (DME) infusion pump, also capped at $35 per month with no deductible.
  • No Deductibles: You do not have to pay a yearly deductible before the $35 cap kicks in for covered insulin.
  • Multiple Months: If you order a three-month supply, you will pay no more than $105 total per covered product ($35 per month).
  • Official Information: You can review official updates and covered products directly on the Medicare Insulin Coverage Page.

What is the current average cost of insulin?

The standard out-of-pocket cost for insulin for most patients in the U.S. has stabilized around $35 or less per month due to federal caps, manufacturer savings programs, and generic options.

Cost Breakdown Without Savings Programs (List Prices)

  • Vials: Typically range from $100 to $300+ per individual 10mL vial before insurance or discounts.
  • Pre-filled Pens: Often range from $80 to $300+ per pack depending on the brand and type.
  • Annual Spending: Historically, average annual out-of-pocket or list costs without caps ranged from $3,800 to nearly $6,000 per year.

Affordability Options and Caps

  • Medicare: Monthly out-of-pocket costs are capped at $35 for Medicare Part B and Part D recipients.
  • Commercial Insurance: Capped at $25 to $100 per month in nearly 30 states.
  • Manufacturer Savings: Programs from major makers like Eli Lilly, Novo Nordisk, and Sanofi limit out-of-pocket cash pay to $35 per month for eligible uninsured patients using savings cards.
  • Generic and Budget Alternatives: Older human insulins (like Walmart's ReliOn) cost around $25 per vial, and state-backed initiatives like California's CalRx provide options starting around $11 per pen.

Verify: Yes, insulin costs about $10 to make but sells for nearly $300

9 related questions found

What is the cheapest insulin without insurance?

Uninsured patients can buy traditional human insulin (like Novolin ReliOn) over-the-counter at major pharmacies like Walmart or CVS for around $25 per vial.

Cheap Insulin Options and Programs

  • Over-the-Counter Vials: Older human insulins (Novolin R and Novolin N) cost about $25 to $45 per vial without insurance. These require careful meal and timing management.
  • Manufacturer Savings Programs: Major companies cap modern analog insulins at $35 per month for uninsured people through dedicated savings initiatives:
    • Eli Lilly: The Lilly Insulin Value Program caps costs at $35 a month.
    • Sanofi: The Insulins Valyou Savings Program reduces costs to $35 a month.
    • Novo Nordisk: Offers savings options and patient assistance programs for qualifying low-income or uninsured individuals.
  • Discount Cards: Using services like GoodRx or SingleCare can lower brand-name and generic biosimilar prices (such as insulin glargine) significantly at local pharmacies.

What is the 3-hour rule for diabetics?

The 3-hour rule for diabetes is a safety guideline that tells patients to wait at least three hours between correction doses of rapid-acting insulin to prevent dangerous insulin stacking.

How the Rule Works

  • Insulin Stacking: This happens when you take a second correction dose of rapid-acting insulin while the first dose is still active in your body.
  • Timing: Rapid-acting insulin starts working in about 15 minutes, peaks at 1 hour, and keeps working for 2 to 4 hours.
  • The Wait: Giving another correction shot too soon creates a cumulative insulin overdose. This causes severe low blood sugar, or hypoglycemia.

Key Exceptions and Guidelines

  • Meals Restart the Clock: If you eat food containing carbohydrates within that 3-hour window, you must take insulin to cover those carbs. However, you should calculate insulin strictly for the food, not as an extra high-blood-sugar correction. Taking insulin for food resets the 3-hour timer for your next correction dose.
  • High Readings within 3 Hours: If your blood sugar stays high before the 3-hour mark, avoid taking another shot. Instead, try a light walk or wait until the active insulin finishes working.

What do diabetics do if they can't afford insulin?

If you cannot afford insulin, you should contact your doctor immediately to explore lower-cost alternatives, apply for manufacturer patient assistance programs, or go to a hospital emergency room if you are completely out of medicine.

Never ration or skip your insulin doses, as this can cause a life-threatening emergency called diabetic ketoacidosis (DKA).

Immediate Financial Relief and Programs

  • Manufacturer Caps: Major insulin makers cap out-of-pocket costs at $35 a month for many eligible patients. Check programs from Lilly Insulin Value Program, Novo Nordisk (Novocare), or Sanofi.
  • Access Tools: Use GetInsulin.org to find a personalized action plan based on your income, location, and prescription needs.
  • Immediate Emergency Supply: Some manufacturers offer a one-time, short-term emergency supply of insulin if you are at immediate risk of running out.

Alternative Low-Cost Options

  • Talk to Your Doctor: Ask your physician to prescribe older, generic, or lower-cost brands of insulin.
  • Over-the-Counter Insulins: Some pharmacies sell older formulations (like Regular or NPH insulin) without a prescription for a lower price. Use these only with caution and guidance from a doctor, as they are harder to manage and raise the risk of dangerous blood sugar drops.
  • Community Health Centers: Local clinics often provide sliding-scale fees or samples to patients in financial distress.

Is insulin still overpriced?

Insulin out-of-pocket costs have dropped significantly for many patients, but list prices and costs for uninsured or underinsured people without specific savings programs can still be high.

What Has Changed

  • Medicare Caps: Monthly out-of-pocket costs for insulin are capped at $35 for Medicare Part B and Part D beneficiaries.
  • Manufacturer Reductions: Major insulin manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) have voluntarily cut list prices or introduced savings programs that cap out-of-pocket costs at around $35 per month for many patients.
  • State Laws: Many states have enacted copay caps ranging from $25 to $100 per month for state-regulated private insurance plans.

Where Costs Remain High

  • List Prices: The underlying list prices set by pharmaceutical companies remain high, meaning costs can spike if a patient does not use specific manufacturer savings cards, assistance programs, or qualifying insurance plans.
  • Gaps in Coverage: Universal federal caps for all commercial private insurance or uninsured individuals still depend on specific programs rather than a single comprehensive federal law.

You can check specific affordability options for your situation through the American Diabetes Association Affordable Insulin Guide.

Is there a generic for insulin?

Yes, lower-cost authorized generics and biosimilar (highly similar) options exist, though they are technically classified as biologics rather than traditional small-molecule generic drugs.

Available Options

  • Authorized Generics: Major manufacturers sell unbranded, lower-priced versions of their own popular brand-name insulins in the exact same formulation. Examples include insulin lispro (generic for Humalog) and insulin aspart (generic for NovoLog).
  • Biosimilars: Interchangeable alternatives made by other companies can be substituted by a pharmacist without calling your doctor. An example is Semglee (biosimilar for Lantus).
  • Older Human Insulins: Over-the-counter human insulins like Humulin R or Novolin R are older formulations available at lower flat cash prices (such as through Walmart's ReliOn brand), though they work differently than modern analog insulins.

If you need help finding affordable options, you can visit Getinsulin.org for guidance.